혈액가스 및 전해질 분석기 시장 규모, 점유율, 동향 분석 : 제품별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

The global blood gas and electrolyte analyzer market size was valued at USD 3.0 billion in 2025 and is projected to grow from USD 3.2 billion in 2026 to USD 4.3 billion in 2033, at a CAGR of 4.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 43.0% in 2025. The market's growth is attributed to the rising prevalence of chronic diseases, the growing geriatric population, and increasing regulatory support and funding for the development of novel blood gas and electrolyte analyzers.

Chronic diseases such as diabetes, cardiovascular diseases, and chronic respiratory conditions are becoming common due to various factors, including lifestyle changes and urbanization. These conditions require continuous monitoring and management. Chronic diseases lead to complications that require blood gas and electrolyte analysis. For instance, diabetes can lead to diabetic ketoacidosis, a condition that necessitates the monitoring of blood pH and electrolyte levels. Similarly, cardiovascular diseases can result in heart failure, demanding regular checks of blood oxygen levels and electrolyte balance. As the prevalence of these diseases rises, the demand for blood gas and electrolyte analyzers is growing.

The growing geriatric population worldwide is a significant factor driving demand for blood gas and electrolyte analyzers. Aging is associated with a higher prevalence of chronic respiratory diseases, cardiovascular disorders, kidney dysfunction, and other age-related conditions that require continuous monitoring and clinical management. Blood gas and electrolyte analyzers play a critical role in assessing parameters such as pH, oxygen, and carbon dioxide levels, and electrolyte balance, supporting diagnosis and treatment decisions in critical care, respiratory care, emergency medicine, and surgical settings. For instance, according to data released by the U.S. Census Bureau in June 2025, the U.S. population aged 65 and older reached approximately 61.2 million in 2024, accounting for 18.0% of the total population, up from 59.3 million in 2023. The continued growth of the aging population is expected to increase the incidence of chronic and acute health conditions, thereby supporting the adoption of blood gas and electrolyte analyzers across healthcare settings.

Regulatory support and funding are crucial factors driving the market. These analyzers are essential for critical care, emergency departments, and clinical laboratories, providing vital information about patients' respiratory & metabolic status. Governments across various regions have been focusing on improving healthcare infrastructure and quality. Regulatory bodies have implemented stringent guidelines and standards for medical devices, ensuring the reliability, accuracy, and safety of blood gas & electrolyte analyzers. This regulatory environment helps build trust among healthcare providers and patients, promoting the adoption of these devices. Furthermore, with the expansion of healthcare facilities, mainly in rural and remote areas, there is a growing demand for advanced medical equipment. New hospitals and clinics need the latest diagnostic technologies to provide high-quality care, driving the market demand. Regulatory bodies and governments conduct awareness programs and provide training for healthcare professionals on the latest medical technologies. This helps increase the adoption of new devices as healthcare providers become more knowledgeable about the benefits and usage of blood gas & electrolyte analyzers.

However, the high cost of advanced analyzers is a key factor constraining market growth. These analyzers integrate advanced technology and features that deliver precise & rapid results, which are crucial in critical care. Moreover, their high cost makes them less accessible to many healthcare facilities, especially in the developing countries of Southeast Asia, where budget constraints are a significant concern. In addition to the initial purchase price, advanced analyzers require ongoing expenditures for consumables such as reagents & cartridges, as well as regular maintenance. These recurring costs can add up, raising the overall cost of ownership. Healthcare providers may be hesitant to invest in such equipment due to the long-term financial commitment required.

Global Blood Gas And Electrolyte Analyzer Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global blood gas and electrolyte analyzer market report based on product, end-use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

Instruments

• Instrument, by Type
  • Bench Top
  • Portable
• Instrument, by Brand
  • I-STAT
  • epoc
  • GEM Premier (3500& 5000)
  • ABL Flex (90 and 800)
  • Cobas
  • RAPID Series
  • Others

Consumables

• End-Use Outlook (Revenue, USD Billion, 2021 - 2033)

Clinical Laboratory

Point-of-care

Diagnostic Centers

Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

• U.S.
• Canada

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• Japan
• China
• India
• South Korea
• Australia
• Singapore
• Malaysia
• Indonesia
• Thailand
• Vietnam
• Philippines

Latin America

• Brazil
• Mexico
• Argentina

Middle East and Africa

• South Africa
• Saudi Arabia
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and end-use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Gas and Electrolyte Analyzer Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing prevalence of chronic diseases
    • 3.2.1.2. Rising geriatric population
    • 3.2.1.3. Increasing regulatory support and funding
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced analyzers
    • 3.2.2.2. Shortage of skilled professionals
• 3.3. Blood Gas and Electrolyte Analyzer Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Blood Gas and Electrolyte Analyzer Market: Product Estimates & Trend Analysis

• 4.1. Global Blood Gas and Electrolyte Analyzer Market: Product Dashboard
• 4.2. Global Blood Gas and Electrolyte Analyzer Market: Product Movement Analysis
• 4.3. Global Blood Gas and Electrolyte Analyzer Market by Product, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.2. Instruments, by Type
  • 4.4.3. Bench Top
    • 4.4.3.1. Benchtop instruments market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.4. Portable
    • 4.4.4.1. Portable instruments market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.5. Instruments, by Brand
  • 4.4.6. I-STAT
    • 4.4.6.1. I-STAT market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.7. epoc
    • 4.4.7.1. epoc market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.8. GEM Premier (3500& 5000)
    • 4.4.8.1. GEM Premier (3500& 5000) market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.9. ABL Flex (90 and 800)
    • 4.4.9.1. ABL Flex (90 and 800) market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.10. Cobas
    • 4.4.10.1. Cobas market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.11. Portable RAPID Series
    • 4.4.11.1. RAPID series market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.12. Others
    • 4.4.12.1. Others market estimates and forecasts 2021 - 2033 (USD Million)
• 4.5. Consumables
  • 4.5.1. Consumables market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 5. Blood Gas and Electrolyte Analyzer Market: End Use Estimates & Trend Analysis

• 5.1. Global Blood Gas and Electrolyte Analyzer Market: End Use Dashboard
• 5.2. Global Blood Gas and Electrolyte Analyzer Market: End Use Movement Analysis
• 5.3. Global Blood Gas and Electrolyte Analyzer Market by End Use, Revenue
• 5.4. Clinical Laboratory
  • 5.4.1. Clinical laboratory market estimates and forecasts 2021 - 2033 (USD Million)
• 5.5. Point-of-care
  • 5.5.1. Point-of-care market estimates and forecasts 2021 - 2033 (USD Million)
• 5.6. Diagnostic Centers
  • 5.6.1. Diagnostic centers market estimates and forecasts 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 6. Blood Gas and Electrolyte Analyzer Market: Regional Estimates & Trend Analysis by Product and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2021 - 2033:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.6. Singapore
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Japan market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.7. Malaysia
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. China market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.8. Indonesia
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. India market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.9. Thailand
    • 6.5.9.1. Key country dynamics
    • 6.5.9.2. Regulatory framework/ reimbursement structure
    • 6.5.9.3. Competitive scenario
    • 6.5.9.4. Australia market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.10. Vietnam
    • 6.5.10.1. Key country dynamics
    • 6.5.10.2. Regulatory framework/ reimbursement structure
    • 6.5.10.3. Competitive scenario
    • 6.5.10.4. South Korea market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.5.11. Philippines
    • 6.5.11.1. Key country dynamics
    • 6.5.11.2. Regulatory framework/ reimbursement structure
    • 6.5.11.3. Competitive scenario
    • 6.5.11.4. South Korea market estimates and forecasts 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Mexico market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecasts 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2021 - 2033 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Abbott
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Meizhou Cornley High-Tech Co., Ltd.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Radiometer Medical ApS
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. EDAN Instruments, Inc.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Erba Mannheim
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. F. Hoffmann-La Roche Ltd
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Fortress Diagnostics
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Werfen
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. LifeHealth
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Medica Corporation
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. OPTI Medical Systems, Inc.,
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Sensa Core
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Siemens Healthineers AG
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives